Spyre Therapeutics Inc
Spyre Therapeutics Inc (SYRE) Options Open Interest
SYRE options open interest is 1,274 contracts. The 2-week average daily volume is 297 contracts across the chain.
Read more
Monitoring SYRE open interest helps you see where real money is positioned on Spyre Therapeutics Inc's options and which strikes are attracting the most commitment from traders. Spyre Therapeutics Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor SYRE options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising SYRE options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Spyre Therapeutics Inc to settle.
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies.
In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where SYRE open interest is concentrated. Our scanner maps Spyre Therapeutics Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Spyre Therapeutics Inc's options open interest as the signal it is, not as an afterthought.
| 90.00 | 1.00 | 4.90 | 2.95 | 61% | +0.3915 | 32 |
| 95.00 | 0.10 | 5.00 | 2.55 | 76% | +0.3036 | 14 |
| 85.00 | 3.10 | 7.50 | 5.30 | 64% | +0.5597 | 5 |
| 110.00 | — | 5.00 | 5.00 | 162% | +0.3047 | 4 |
| 105.00 | — | 5.00 | 5.00 | 147% | +0.3244 | 3 |
| 85.00 | 2.80 | 6.20 | 4.50 | 66% | -0.4404 | 210 |
| 70.00 | — | 4.90 | 4.90 | 164% | -0.2266 | 159 |
| 95.00 | 8.50 | 12.70 | 10.60 | 61% | -0.7527 | 55 |
| 80.00 | 0.10 | 4.00 | 2.05 | 61% | -0.2724 | 31 |
| 90.00 | 5.60 | 9.50 | 7.55 | 69% | -0.5902 | 27 |
As of September 28, 2026
Follow the money
Track SYRE open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→